MS Briefs

Examining Pseudobulbar Affect in Multiple Sclerosis

Neurol Clin Pract; 2018 Dec; Fitzgerald, et al


 

The prevalence of pseudobulbar affect (PBA) in multiple sclerosis (MS) is low, according to a recent study, but similar symptoms may co-occur or overlap with depression, highlighting the importance of concomitant assessment of mood when evaluating potential PBA. Furthermore, PBA may be associated with cognitive impairment in people with MS. North American Research Committee on MS (NARCOMS) registry participants completed the Center for Neurologic Study-Lability Scale (CNS-LS), a validated 7-question self-report measure of PBA. Researchers categorized individuals as PBA-positive (PBA[+]) if they had a composite score ≥17 without current depression. Participants also reported their demographic characteristics and their clinical characteristics using Patient-Determined Disease Steps and Performance Scales. They found:

  • Of the 8,136 responders, 574 (7%) had scores ≥17 on the CNS-LS; however, only 200 (2.5%) individuals had scores ≥17 without comorbid depression, of whom only 22 (11%) reported a diagnosis of PBA.
  • PBA(+) individuals tended to be younger (mean [SD] 53.4 [11.0] vs 57.2 [10.3] years), non-white (13% vs 9%), and have lower socioeconomic status (≤$30,000 annual income: 28% vs 22%).
  • In multivariable models, PBA(+) was associated with increased odds of more severe cognitive impairment.

Fitzgerald KC, Salter A, Tyry T, Fox RJ, Cutter G, Marrie RA. Pseudobulbar affect.

Prevalence and association with symptoms in multiple sclerosis. Neurol Clin Pract . 2018;8(6):472-481. doi:10.1212/CPJ.0000000000000523.

Recommended Reading

Dietary sodium still in play as a potential MS risk factor
ICYMI Multiple Sclerosis
Virus-Specific T-Cell Infusions May Resolve Progressive Multifocal Leukoencephalopathy
ICYMI Multiple Sclerosis
Real-world data reveal long-lasting effects achieved with RRMS treatments
ICYMI Multiple Sclerosis
Food allergies linked to increased MS relapses, lesions
ICYMI Multiple Sclerosis
Integrated analysis suggests cladribine’s safety in MS
ICYMI Multiple Sclerosis
Does rituximab delay disability progression in patients with secondary progressive MS?
ICYMI Multiple Sclerosis
Daclizumab beta may be superior to interferon beta on MS disability progression
ICYMI Multiple Sclerosis
Interferon Beta May Not Affect Pregnancy Outcomes in MS
ICYMI Multiple Sclerosis
Autologous Hematopoietic Stem Cells May Treat Aggressive MS Effectively
ICYMI Multiple Sclerosis
DMTs, stem cell transplants both reduce disease progression in MS
ICYMI Multiple Sclerosis